| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 07/03/2002 | EP1218509A2 Fibroblast growth factor-like polypeptides |
| 07/03/2002 | EP1218412A2 Human g-protein coupled receptor |
| 07/03/2002 | EP1218408A1 32 human secreted proteins |
| 07/03/2002 | EP1218403A2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
| 07/03/2002 | EP1218381A2 AMINO SUBSTITUTED PYRAZOLO 1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO 1,5-a]-1,3,5-TRIAZINES |
| 07/03/2002 | EP1218373A2 2-pyrazolin-5-ones as tyrosine kinase inhibitors |
| 07/03/2002 | EP1218369A1 INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES |
| 07/03/2002 | EP1217975A1 Using quaternary ammonium salts for transdermal drug delivery |
| 07/03/2002 | EP0680346B1 Method of increasing the concentration of nitric oxide in blood |
| 07/03/2002 | CN1357003A 类固醇衍生物 Steroid derivatives |
| 07/03/2002 | CN1356912A Trapping agent for blood carbonyl compounds |
| 07/03/2002 | CN1356908A Pharmaceutical formulation comprising low molecular weight thrombin inhibitor and its prodrug |
| 07/03/2002 | CN1356905A Leaves of cajanus cajan(L.) millsp and extract, formulation and uses thereof |
| 07/03/2002 | CN1356902A IL-8 receptor antagonists |
| 07/03/2002 | CN1356899A IL-8 receptor antagonists |
| 07/03/2002 | CN1356338A Separation, synthesis and application in medicine for P6A'S metabolic product |
| 07/03/2002 | CN1086946C Thrombus dissolving capsule |
| 07/03/2002 | CN1086942C Application of butyl phthalide in preparing medicines curing thrombosis and thrombocyte coagulation |
| 07/02/2002 | US6414020 Antiproteolytic amidino or derivative useful for treating pencreatitis, thrombosis, ischemia, stroke, restenosis, emphysema or inflammation |
| 07/02/2002 | US6413996 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 07/02/2002 | US6413980 Nitrogen containing heterobicycles as factor Xa inhibitors |
| 07/02/2002 | US6413952 Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal |
| 07/02/2002 | US6413931 Peptide inhibitor of fibrinogen blood clotting |
| 07/02/2002 | US6413737 Ecarin prothrombin protease and methods |
| 07/02/2002 | US6413731 Methods of screening for compounds which bind to a human SNORF36A receptor |
| 07/02/2002 | US6413444 Nucleation by subcooling or adding crushed chuck ice; high fluidity and cooling capacity; stable; protective hypothermia of human organs/tissue during medical treatment |
| 07/02/2002 | CA2201714C Method for isolation of highly pure von willebrand factor |
| 07/02/2002 | CA2133203C Hybrid human/porcine factor viii |
| 07/02/2002 | CA2047283C Pyrazolopyridine compound and processes for preparation thereof |
| 06/27/2002 | WO2002050290A1 A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell |
| 06/27/2002 | WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | WO2002050125A2 Glycosaminoglycans derived from k5 polysaccharide having high antithrombin activity and process for their preparation |
| 06/27/2002 | WO2002050073A1 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 06/27/2002 | WO2002050056A1 Benzylamine derivatives and their use as thrombin inhibitors |
| 06/27/2002 | WO2002050051A1 Chemical compounds |
| 06/27/2002 | WO2002050039A1 Urea and urethane derivatives as integrin inhibitors |
| 06/27/2002 | WO2002050034A2 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002049993A2 High affinity small molecule c5a receptor modulators |
| 06/27/2002 | WO2002049694A2 Sterile bicarbonate-free dialysis concentrate solutions |
| 06/27/2002 | WO2002049665A2 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings |
| 06/27/2002 | WO2002049654A1 Shark meat extract |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049413A2 Thrombopoietin mimetics |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2002010154A3 Substituted heterocyclic amides |
| 06/27/2002 | WO2001077375A3 Diagnosis of diseases associated with gene regulation |
| 06/27/2002 | WO2001076640A3 Chemically modified novel erythropoietin stimulating protein compositions and methods |
| 06/27/2002 | WO2001073025A3 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 06/27/2002 | WO2001072293A3 Antiprogestins with partial agonist activity |
| 06/27/2002 | US20020082620 Bioactive materials for aneurysm repair |
| 06/27/2002 | US20020082413 PGC-1, a novel brown fat PPARgamma coactivator |
| 06/27/2002 | US20020082388 Polypeptide for use in the treatment, diagnosis and prevention of cancer, nervous system and developmental disorders |
| 06/27/2002 | US20020082292 Agonists of peroxisome proliferator activated receptor (PPAR) alpha and/or gamma |
| 06/27/2002 | US20020082266 Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore |
| 06/27/2002 | US20020082256 Compounds useful as anti-inflammatory agents |
| 06/27/2002 | US20020082253 Novel isoxazoline fibrinogen receptor antagonists |
| 06/27/2002 | US20020082246 Prophylaxis and therapy of disorders in the course of which an increased activity of matrix-degrading enzymes is involved; these include degenerative joint disorders such as osteoarthroses and disorders of connective tissue |
| 06/27/2002 | US20020082241 Adenosine as antithrombotic |
| 06/27/2002 | US20020082219 Dendroaspis(green mamba snake) natriuretic peptide has at least one activity selected from the group consisting of vasodilation, antriuresis, diuresis and renin-suppressing activity |
| 06/27/2002 | US20020082202 Screening methods using ligands of the neutropeptide receptor HFGAN72 |
| 06/27/2002 | US20020081734 Modified muteins of erythropoietin derived from in vitro or in vivo expression system of microorganism |
| 06/27/2002 | US20020081695 Nucleotide sequences coding polypeptide for use in the treatment of blood disorders, gout, kidney stones, Lesch-Nyhan syndrome, renal failure and uricaciduria |
| 06/27/2002 | US20020081290 Protein kinase homologs |
| 06/27/2002 | CA2436288A1 Thrombopoietin mimetics |
| 06/27/2002 | CA2432760A1 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | CA2431986A1 Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings |
| 06/27/2002 | CA2431964A1 Conjugates of erythropoietin (pep) with polyethylene glycol (peg) |
| 06/27/2002 | CA2431588A1 Benzylamine derivatives and their use as thrombin inhibitors |
| 06/27/2002 | CA2431147A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | CA2431074A1 Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1) |
| 06/27/2002 | CA2431028A1 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 06/27/2002 | CA2431023A1 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | CA2423331A1 Shark meat extract |
| 06/26/2002 | EP1217000A1 Inhibitors of factor Xa and factor VIIa |
| 06/26/2002 | EP1216986A2 Novel delta dicarbonyl compounds and methods for using same |
| 06/26/2002 | EP1216709A1 Use of activated coagulation factor VII for treating thrombolytic therapy-induced major bleedings |
| 06/26/2002 | EP1216259A1 SIGNAL SEQUENCES FOR THE PRODUCTION OF LEU-HIRUDINE VIA SECRETION BY i E. COLI /i IN A CULTURE MEDIUM |
| 06/26/2002 | EP1216248A2 Triazolopyrimidine derivatives |
| 06/26/2002 | EP1216247A1 Imidazoimidazoles and triazoles as anti-inflammatory agents |
| 06/26/2002 | EP1216245A1 Pharmaceutically active sulfonyl hydrazide derivatives |
| 06/26/2002 | EP1216241A1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216238A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 06/26/2002 | EP1216235A1 Quinazolinones |
| 06/26/2002 | EP1216231A2 INHIBITORS OF FACTOR Xa |
| 06/26/2002 | EP1216230A2 Fused cycloheptane and fused azacycloheptane compounds and their use as integrin receptor antagonists |
| 06/26/2002 | EP1216228A2 BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa |
| 06/26/2002 | EP1216225A2 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 06/26/2002 | EP1216222A2 Novel derivatives of dicarboxylic acid having pharmaceutical properties |
| 06/26/2002 | EP1216045A2 Vasopressin agonist formulation and process |
| 06/26/2002 | EP1216037A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents |
| 06/26/2002 | EP1216033A1 Vasopressin antagonist formulation and process |
| 06/26/2002 | EP1049689B1 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists |
| 06/26/2002 | CN1355850A Hyaluronidase from hirudinaria manillensis, isolation, purification and recombinant method of production |
| 06/26/2002 | CN1355842A Methods for making proteins containing free cysteine residues |